Expression of immune-related molecules in glioblastoma multiform cells

  • Wu An-hua 
  • Wang Yun-jie 
  • Zhang Xue 
  • Walter C. Low


Objective: To investigate the expression of immune-related molecules in glioblastoma multiform(GBM) cells. Methods: The expression of major histocompatibility complex (MHC), β2-microglobulin, Fas, CD80 and CD86 molecules on the surface of GBM cells were evaluated by flow cytometry. The expression of TAP-1, TAP-2 and Tapasin in the GBM cells were evaluated by RT-PCR method. Results: MHC class I, β2 microglobulin, TAP-1, TAP-2 and tapasin were expressed in most GBM cell lines. Except U87, there was no MHC class II molecule expression on any of the other GBM cell lines. Fas was expressed on all the GBM cell lines examined. Conclusion: The mechanism by which GBM escapes immune surveillance may involve down regulation of expression of MHC class I molecules and MHC class II molecules. MHC class I positive GBM may be the suitable target of immunotherapy.

Key words

GBM (glioblastoma multiform) Immune MHC (major histocompatibility complex) 

CLC number



  1. [1]
    Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy[J]. Neurosurgery 2000; 46: 778–91.PubMedCrossRefGoogle Scholar
  2. [2]
    Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: anin vitro model for the assessment of tumor vaccine[J]. Cancer Res 2001; 61: 6445–50.PubMedGoogle Scholar
  3. [3]
    Ni HT, Spellman SR, Jean WC, et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas[J]. J Neurooncol2001;51: 1–9.PubMedCrossRefGoogle Scholar
  4. [4]
    Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration[J]. Cancer Res 2001; 61: 842–7.PubMedGoogle Scholar
  5. [5]
    Morford LA, dix AR, Brooks WH, et al. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors[J]. J Neurosurg 1999; 91: 935–46.PubMedGoogle Scholar
  6. [6]
    Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens[J]. J Neurosurg 1999; 90: 1115–24.PubMedCrossRefGoogle Scholar
  7. [7]
    Elliott LH, Brooks WH, Roszman TL. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumor[J]. J Immunol 1984; 132: 1208–15.PubMedGoogle Scholar
  8. [8]
    McVicar DW, Davis DF, merchant RE. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect[J]. J Neurosurg 1992; 76:251–60.PubMedGoogle Scholar
  9. [9]
    Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors[J]. J Neuroimmunol 1999; 100: 216–32.PubMedCrossRefGoogle Scholar
  10. [10]
    Morford LA, Elliott LH, Carlson SL, et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors[J]. J Immunol 1997; 159: 4415–25.PubMedGoogle Scholar
  11. [11]
    Eifuku R, Takenoyama M, Yoshino I, et al. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes[J]. Int J Clin Oncol 2001; 6: 34–9.PubMedCrossRefGoogle Scholar
  12. [12]
    Serrano A, Tanzarella S, Lionello I, et al. Repression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment[J]. Int J Cancer 2001; 94: 243–51.PubMedCrossRefGoogle Scholar
  13. [13]
    Alimonti J, Zhang QJ, Gabathuler R, et al. TAP expression provides a general method for improving the recognition of malignant cellsin vivo[J]. Nat Biotechnol 2000; 18: 515–20.PubMedCrossRefGoogle Scholar
  14. [14]
    Li S, paulsson KM, Chen S, et al. Tapasin is required for efficient peptide binding to transporter associated with antigen processing[J]. J Biol Chem 2000; 275: 1581–86.PubMedCrossRefGoogle Scholar
  15. [15]
    Murray JL, Hudson JM, Ross MI, et al. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression[J]. J Immunother 2000; 23: 28–35.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Journal of Cancer Research 2003

Authors and Affiliations

  • Wu An-hua 
    • 1
    • 2
  • Wang Yun-jie 
    • 1
  • Zhang Xue 
    • 2
  • Walter C. Low
    • 3
  1. 1.Department of NeurosurgeryChina Medical UniversityShenyangChina
  2. 2.Department of Cell BiologyChina Medical UniversityShenyangChina
  3. 3.Department of NeurosurgeryUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations